This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
The American Diabetes Association (ADA) and Abbott have announced a collaboration aimed at better understanding how diabetes technology like continuous glucose monitoring (CGM) systems can help people living with diabetes make informed decisions about their food and activity. CGM systems, like those made by Abbott, are an important tool in helping people manage their diabetes by offering personalized, real-time data on how food and activity affect glucose levels.
Abbott is providing a $2.65 million grant over the next three years to the ADA to enable the association to:
- Engage with top healthcare professionals and key opinion leaders to evaluate existing clinical evidence on the use of CGM systems for personalized, therapeutic nutrition.
- Launch two pilot programs targeted at adults with Type 2 diabetes to gain a deeper understanding of the role a CGM can play in personalized therapeutic nutrition. These programs will leverage CGM data to understand how they help people with diabetes achieve their objectives, which include modifications to their nutritional intake and dietary habits.
- Host roundtable discussions in collaboration with renowned health care experts to review and evaluate the existing clinical evidence. These discussions will investigate the role of therapeutic nutrition using CGM data and its potential to inform nutrition recommendations.
“What people with diabetes eat is a critical part of managing their diabetes,” says Charles “Chuck” Henderson, chief executive officer of the ADA. “Personalized nutrition using CGMs has the potential to revolutionize diabetes management by providing individuals with more data and tools to manage their glucose levels, improve their quality of life, and reduce the risk of diabetes-related complications. The ADA is grateful to Abbott for its continued support of our mission to improve the lives of people impacted by diabetes.”
“Abbott’s FreeStyle Libre technology can be a critical tool for all people living with diabetes, not only those on insulin,” says Robert B. Ford, chairman and chief executive officer, Abbott. “We look forward to working with the American Diabetes Association to gather further evidence to show how the technology we designed to be affordable and accessible can provide personalized insights to help people make informed decisions about their food and activity.”
